A Revolution in
Eye Disease Treatment

ABOUT THE COMPANY
We are an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives.
Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences® seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
  • LEADERSHIP TEAM
  • BOARD OF DIRECTORS
grafic lines 4
Paul Badawi
FOUNDER & CHIEF EXECUTIVE OFFICER
Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.
Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

read more read less
Dr. David Badawi, MD
FOUNDER & CHIEF TECHNOLOGY OFFICER
Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™Microstent, and TearCare® System.
David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease.

He also oversees the preclinical and clinical development of each of the company’s products. In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs. David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

read more read less
Ali Bauerlein
CHIEF FINANCIAL OFFICER
Chief Financial Officer of Sight Sciences, Inc. She brings to Sight Sciences experience leading global finance and accounting functions, including revenue management, U.S. Securities and Exchange Commission (“SEC”) reporting, investor relations and business development.
Ali Bauerlein joined Sight Sciences from Inogen, a medical technology company offering innovative respiratory products for use in the homecare setting. Ms. Bauerlein cofounded Inogen in 2001 and served as its Chief Financial Officer from 2009 through 2021.

In this role, Ms. Bauerlein oversaw the global finance and accounting functions, including revenue management, financial planning and analysis, strategic and tactical cost analysis and forecasting, treasury, SEC reporting, investor relations, business development, risk management, tax, and treasury functions, as the Inogen scaled from start-up operations to over $350 million in annual sales. Ali has also served as a member of the board of directors of Pear Therapeutics, Inc, a software-based digital therapeutics company, since December 2021, and as a member of the board of directors of Gelesis Holdings, Inc, a biotherapeutics company since January 2022. She serves as chair of the Audit Committees of both Pear and Gelesis. Ms. Bauerlein also serves as a member of the board of directors of Koya Medical, Inc., a private company, since January 2021. Ali received a B.A. in economics/mathematics with high honors from the University of California, Santa Barbara.

read more read less
Dr. Reay H. Brown, MD
CHIEF MEDICAL OFFICER
Chief Medical Officer (CMO) of Sight Sciences, Inc. In his role as CMO, Dr. Brown works closely with the Company's research and development team on making improvements to existing products and on new product innovation, as well as with Sight Sciences' clinical and commercial teams.
Reay H. Brown, M.D. is a board certified ophthalmologist specializing in glaucoma and cataract surgery with intraocular lens implantation.

He has been in practice in Atlanta since 1988. Dr. Brown has published more than 90 peer reviewed articles on glaucoma and cataract surgery. He has served as chairman of the ASCRS Glaucoma Committee and is currently the Glaucoma Editor of EyeWorld magazine. He recently received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia to receive this prestigious award. He received the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute) and the 2014 Innovator Award form the American Glaucoma Society. He has given many named lectures all over the world including the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. He was selected to give the Charles D. Kelman Innovator Lecture in 2017. This international award honors Dr. Kelman, the inventor of phacoemulsification, a huge step forward in successful cataract surgery outcomes. This award has only been given to 33 innovators in eye surgery since its inception in 1985.

Dr. Brown and his wife, Dr. Mary G. Lynch, a Professor at Emory, have been awarded 25 patents for new devices and instruments to improve glaucoma and cataract surgery. Their patents on trabecular bypass are the fundamental patents for several innovative devices implanted into the outflow channel of the eye. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and by a separate peer survey in Atlanta Magazine as one of the best ophthalmologist in Atlanta.

Dr. Brown earned his undergraduate degree from Harvard College Cum laude and completed medical school at the University of Michigan. He trained in ophthalmology at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident.

Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999.

Drs. Brown and Lynch have two daughters, Veronica and Annie. Rounding out their household is, Lily, a loving English Mastiff. Dr. Brown is an avid runner, enjoys playing tennis and traveling with his family.

read more read less
Matt Link
CHIEF COMMERCIAL OFFICER
Chief Commercial Officer (CCO) of Sight Sciences.
Mr. Link has more than 20 years of experience building teams and leading innovation in the healthcare and medical technology industries, most recently serving as Managing Partner at Orion Healthcare Advisors, LLC, a consulting services provider.

Before Orion, Mr. Link spent nearly 15 years in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine surgery and orthopedics, where he designed and executed strategies that supported the company’s revenue growth from less than $100 million to over $1 billion. Mr. Link joined NuVasive as an Area Business Manager and rose to the level of President where his responsibilities included oversight of global business units in spine, neurophysiology and orthopedics. Prior to NuVasive, Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He currently serves as a member of the board of directors of Springbok Analytics, Fibrobiologics and DinamicOR. Additionally, he serves on the board of directors for the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia.

read more read less
Jeremy Hayden
Chief Legal Officer
Leads our legal and compliance functions. Jeremy has more than twenty years’ experience representing successful companies across a variety of industries.
Jeremy commenced his career as a corporate and securities attorney practicing for several international law firms where he specialized in capital markets transactions, M&A and technology transfer transactions.

Since 2012, Jeremy has worked exclusively in senior legal positions for innovative medical device companies, including serving as Assistant General Counsel for Volcano Corporation, General Counsel and Vice President of Business development for Cytori Therapeutics, Inc. and General Counsel for Endologix, Inc. Jeremy holds a J.D. from University of Michigan Law School and an A.B. in Politics from Princeton University.

read more read less
Sam Park
CHIEF OPERATING OFFICER
Sam has more than 25 years of medical device start-up experience in design and operations building pre-revenue companies, and leading them through to acquisition.
Prior to joining Sight Sciences Inc., Sam served as VP of R&D and Operations at SurgRx where he led the development of EnSeal Vessel Sealing System which was purchased by Ethicon-Endo Surgery of J&J.

He also led operations at Novacept from early revenue to its acquisition by Cytyc. Sam has held various other executive and technical positions at Spineview (Expending Innovation), Arthrocare (acquired by Smith and Nephew), CardioGenesis (IPO), and Origin Medsystems (acquired by Eli Lily, later Guidant).

Before entering the medical device industry, Sam worked in aerospace at Hughes Aircraft, and Xerox Designing and Manufacturing Laser Systems.
Sam hold a BS from the University of California Irvine in Mechanical Engineering.

read more read less
Dr. David Badawi, MD
FOUNDER & CHIEF TECHNOLOGY OFFICER
Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™Microstent, and TearCare®.
David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.

In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.

David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

read more read less
Paul Badawi
FOUNDER & CHIEF EXECUTIVE OFFICER
Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare®.
Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

read more read less
Brenda Becker
BOSTON SCIENTIFIC
Brenda Becker has served as a member of our Board since March 2022.

Since 2007, Ms. Becker has served as the Senior Vice President, Global Government Affairs for Boston Scientific. Prior to joining Boston Scientific in 2007, Ms. Becker served in the George W. Bush administration under former Vice President Dick Cheney as Assistant to the Vice President for Legislative Affairs. In that capacity, she advised the Vice President and senior White House staff on legislative strategy from 2004 to 2007. In addition, from 2001 to 2004, Ms. Becker served as the Assistant Secretary for Legislative and Intergovernmental Affairs at the U.S. Department of Commerce where she provided counsel to the Secretary of Commerce and other senior commerce officials. Ms. Becker holds a B.A. in Political Science and Public Administration from Michigan State University and an M.B.A. from Central Michigan University.

read more read less
Staffan Encrantz
ALLEGRO INVESTMENT FUND, L.P.
Staffan Encrantz has served as Chairperson of the Board since 2017.

Mr. Encrantz is currently Chairman of AnaMar AB, ClosingCorp Inc, Evolve Controls, LLC, Nclear Inc, Alestra Ltd., Koncentra Holding AB and the Koncentra Verkstads AB group. He is also a director of GovX, Inc, Oxymetal SAS and several other companies.

Mr. Encrantz is the President and Founder of Allegro Investment Inc., the investment manager of Allegro Investment Fund, L.P., and has served as such since 1997. Mr. Encrantz holds a Bachelor of Law and a Business Studies degree from Uppsala University, Sweden.

read more read less
Erica Rogers
SILK ROAD MEDICAL
Erica Rogers has served as a member of our Board since November 2019.

Since October 2012, Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical, a medical device company. Ms. Rogers also served as a member of the board of directors and member of the compensation and audit committee of Lucira Health, a diagnostics company, from August 2020 to September 2022, and currently serves as an advisor to Alydia Health and Venture Investors. Ms. Rogers holds a B.S. in Zoology from San Diego State University.

read more read less
Catherine Mazzacco
Catherine Mazzacco has served as a member of our Board since June 2023.

Ms. Mazzacco was Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company, and a member of its board of directors, from August 2019 to November 2021. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare, a leading global medical technology, pharmaceutical diagnostics and life sciences company, from February 2018 to May 2019. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories, a major multinational publicly traded healthcare company where she held several global senior operational and strategic leadership roles, including Vice President, Global Commercial Operations, Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served as a member of the board of directors of Krystal Biotech, Inc. since March 2023 and is a member of its Nominating and Corporate Governance Committee and its Commercial Advisory Committee. Ms. Mazzacco is a Member of the Supervisory Board and Remuneration & Nomination Committee of Servier, a privately owned global pharmaceutical company. Ms. Mazzacco holds a Bachelor of Science in Engineering, Option Biotechnology from the University of Compiègne in France.

read more read less
Don Zurbay
PATTERSON COMPANIES
Donald Zurbay has served as a member of our Board since July 2020.

Since October 2022, Mr. Zurbay has served as the Chief Executive Officer of Patterson Companies, a global medical device company. From June 2018 to October 2022, Mr. Zurbay served as the Chief Financial Officer of Patterson Companies. From March 2004 to February 2017, Mr. Zurbay held various leadership positions at St. Jude Medical, Inc., where he most recently served as Vice President and Chief Financial Officer from August 2012 to January 2017. Mr. Zurbay currently serves on the board of Silk Road Medical and served on the board of Avedro, Inc. from July 2017 to November 2019. Mr. Zurbay holds a B.S. in Business Accounting from the University of Minnesota.

read more read less
Dr. Tamara Fountain, MD
Tamara Fountain has served as a member of our Board since July 2022.

Dr. Fountain served as a member of the board of directors from January 2020 to January 2023 and as the 2021 President of the American Academy of Ophthalmology and was named to the board of directors of the American Board of Ophthalmology in January 2022. She has also served as a member of the board of directors of RxSight (NASDAQ: RXST) since January 2022. She has been on faculty at Rush University Medical Center in Chicago since May 1998 where she is professor of ophthalmology and section chair emeritus of ophthalmic plastic and reconstructive surgery. She has maintained a private practice, Ophthalmology Partners, Ltd., on Chicago’s North Shore since December 2000. Dr. Fountain was chair for Alumni Fund Giving at Harvard Medical School from January 2016 to June 2019 and served as President of the American Society of Ophthalmic Plastic and Reconstructive Surgery in 2018 and as a member of the board of directors from January 2016 to January 2020. She served 15 years on the board of directors of Ophthalmic Mutual Insurance Company (“OMIC”). At the end of her term, Dr. Fountain was elected OMIC’s first woman chair of its board of directors and chair of its audit committee, serving January 2014 to December 2015. Dr. Fountain was President of the Illinois Society of Eye Physicians and Surgeons from January 2002 to December 2005. Dr. Fountain received her B.A. in Human Biology from Stanford University, her M.D. from Harvard Medical School, and in 1992, completed her residency in ophthalmology at Johns Hopkins Hospital’s Wilmer Eye Institute.

read more read less
grafic lines 4

Careers at Sight Sciences

For information on current job openings, please contact us at E: jobs@sightsciences.com

At Sight Sciences you’ll have the opportunity to join a team dedicated to revolutionizing the way the ophthalmic and optometric communities think about and treat the leading causes of eye disease. We are seeking candidates with a passion for delivering novel, game-changing technologies and who are committed to improving patient outcomes.

Sight Sciences will process your personal information as described in this Privacy Statement and will be responsible for complying with applicable data protection laws.

We respect your privacy and will treat your personal information as confidential. We will use and share your personal information as described in this Privacy Statement.

Download Privacy Notice for Job Applicants PDF

Benefits at Sight Sciences

Competitive Compensation and Benefits Packages

Competitive Medical, Vision, and Dental plans are available. Flexible spending accounts, commuter benefits, and more!

401k with Employer Match

The employer match acts as an additional contribution to your retirement savings. It's free money from your employer, increasing your savings towards your retirement goals.

Equity

An ESPP program allows employees to participate in Sight Sciences ownership.

Flexible/Paid Time Off, & Sick Leave

Taking PTO is essential for maintaining work-life balance, improving well-being, boosting productivity, and fostering a positive work environment.

Paid Volunteering Hours

Our impactful approach encourages employees to actively engage in community service and contribute to social causes.

Paid Parental Leave

We provide paid time off for employees who become parents through childbirth, adoption, or foster care, allowing them to bond with their new child and manage the demands of parenthood without sacrificing their financial stability or career growth.

Wellness Programs

By providing resources, activities, and incentives that encourage employees to adopt healthy lifestyles. Healthy employees are more energized, focused, and resilient, positively impacting their workplace performance and effectiveness.

Employee Assistance Program

Designed to help employees manage various challenges they may face, including emotional, mental, financial, and other personal concerns.

Learning & Development Opportunities

Crucial for both employees and organizations as they promote professional growth, enhance skills, and drive overall success.

Basic Life, Short Term & Long-term Disability

Basic life, short-term disability (STD), and long-term disability (LTD) benefits are essential components of an employee benefits package that provide financial protection and support for unforeseen circumstances impacting an employee's health and well-being.

Sight Sciences is an Equal Opportunity/Affirmative Action employer

We are an Equal Employment/Affirmative Action employer. We are committed to providing equal employment opportunities to all employees and applicants without regard to race, ethnicity, religion, color, sex, gender, gender identity and/or expression, sexual orientation, national origin, citizenship status, uniform service member status, veteran status, marital status, pregnancy, age, genetic information, disability, ancestry, protected medical condition, or any other protected status in accordance with all applicable federal, state, and local laws.

If you need a reasonable accommodation for any part of the employment process, please contact us by email at jobs@sightsciences.com and let us know the nature of your request and your contact information. Requests for accommodation will be considered on a case-by-case basis. Please note that only inquiries concerning a request for reasonable accommodation will be responded to from this e-mail address.

For more information, view the EEO is the Law Poster and the Sight Sciences Affirmative Action Statement.